A systematic assessment of the relationship between synthetic surfactants and mucosal adjuvanticity

Yoshino, Naoto; Kawamura, Hanae; Sugiyama, Ikumi; Sasaki, Yutaka; Odagiri, Takashi; Sadzuka, Yasuyuki; Muraki, Yasushi

doi:10.1016/j.ejpb.2021.05.010

Cited by 2 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For IN immunization, mice were administered a 10 µL aliquot (5 µL/nostril) of the immunization solution, whereas SC immunization was performed by injecting a 50 µL aliquot of the immunization solution into the interscapular region of the mice. Each mouse was immunized thrice at 0, 7, and 14 days, as previously described [2,21,24].…”

Section: Immunization Of Micementioning

confidence: 99%

“…The particle diameters of the virus antigen and PMB-virus antigen complex were measured using a Zetasizer Nano ZS system (Malvern Instruments Ltd., Worcestershire, UK), as described previously [21,24].…”

Section: Particle Diametermentioning

confidence: 99%

“…Particles with a 100-500 nm diameter are considered suitable for inducing mucosal immunity in IN immunization [29]. Furthermore, our previous studies using surfactants and OVA suggest that the diameter of the surfactant-OVA complex affects their adjuvanticity [24]. Although we did not confirm the transfer of PMB-virus antigen complexes into mucosal tissues in the present study, previous findings on the relationship between particle diameter and adjuvanticity suggest that the diameter of a suitable PMB-virus antigen complex would affect vaccine efficacy.…”

Section: Histopathology Of the Nasal Mucosa Of Immunized Micementioning

confidence: 99%

“…Mixing antigen and PMB results in a particular particle diameter, but why particles of that diameter are formed (the factors that determine the diameter) remains unknown. We measured particle diameters in solutions of OVA mixed with 31 different surfactants but did not identify factors that determine the diameter [24,48]. Thus, the inability to artificially adjust the diameter of the PMB-protein complex is a limitation of PMB.…”

Section: Histopathology Of the Nasal Mucosa Of Immunized Micementioning

confidence: 99%

See 3 more Smart Citations

Suitability of Polymyxin B as a Mucosal Adjuvant for Intranasal Influenza and COVID-19 Vaccines

Yoshino,

Yokoyama,

Sakai

et al. 2023

Vaccines

Self Cite

View full text Add to dashboard Cite

Polymyxin B (PMB) is an antibiotic that exhibits mucosal adjuvanticity for ovalbumin (OVA), which enhances the immune response in the mucosal compartments of mice. Frequent breakthrough infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants indicate that the IgA antibody levels elicited by the mRNA vaccines in the mucosal tissues were insufficient for the prophylaxis of this infection. It remains unknown whether PMB exhibits mucosal adjuvanticity for antigens other than OVA. This study investigated the adjuvanticity of PMB for the virus proteins, hemagglutinin (HA) of influenza A virus, and the S1 subunit and S protein of SARS-CoV-2. BALB/c mice immunized either intranasally or subcutaneously with these antigens alone or in combination with PMB were examined, and the antigen-specific antibodies were quantified. PMB substantially increased the production of antigen-specific IgA antibodies in mucosal secretions and IgG antibodies in plasma, indicating its adjuvanticity for both HA and S proteins. This study also revealed that the PMB-virus antigen complex diameter is crucial for the induction of mucosal immunity. No detrimental effects were observed on the nasal mucosa or olfactory bulb. These findings highlight the potential of PMB as a safe candidate for intranasal vaccination to induce mucosal IgA antibodies for prophylaxis against mucosally transmitted infections.

show abstract

Section: Immunization Of Micementioning

confidence: 99%

Section: Particle Diametermentioning

confidence: 99%